The reference for the odds ratio calculation is the use of drug substrates alone for each subgroup. A) showed the risk of overall anomalies associated with drug interactions in all P-gp substrates; B) showed the risk for specific anomalies (heart, genital, respiratory, musculoskeletal) in drugs previously associated with these anomalies (cimetidine, ranitidine, omeprazole, pantoprazole, morphine, haloperidol, risperidone, quetiapine); C) showed the risk for specific anomalies (heart, musculoskeletal) in P-gp substrates (S) previously associated with these anomalies (cimetidine, ranitidine, risperidone); D) showed the risk for specific anomalies (genital, musculoskeletal) in P-gp substrates/inhibitors (S/I) previously associated with these anomalies (omeprazole, pantoprazole, haloperidol, quetiapine); * substrate/inhibitor, inhibitor, inducer, substrate/inducer, and substrate/inducer/inhibitor; ** substrate/inhibitor, inhibitor, inhibitor/inducer, substrate/ inhibitor/inducer; †Fisher's exact test
